Alumis Inc (ALMS)

$23.37 +0.64 (2.82%)
Market Cap 2.97B
Revenue (ttm) 24.05M
Net Income (ttm) -243.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,011.77%
Debt to Equity Ratio 0.00
Volume 1,412,300
Avg Vol 1,571,352
Day's Range N/A - N/A
Shares Out 127.20M
Stochastic %K 54%
Beta -0.64
Analysts Strong Sell
Price Target $38.40

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibo...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 3 at 2:28 AM
$ALMS RSI: 45.78, MACD: -0.9569 Vol: 1.91, MA20: 24.85, MA50: 26.27 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
laaarsas
laaarsas Mar. 31 at 2:23 PM
$ALMS I see a lot of variation in the price targets for this one. They are not first movers. What’s their niche? How will they brake into the market? Why should one buy Alumis over something else?
1 · Reply
notreload_ai
notreload_ai Mar. 30 at 4:57 PM
$ALMS , $PTGX ... Alumis shares plunged after strong Phase 3 psoriasis data for envudeucitinib. HC Wainwright cuts price target to $25 citing rising competition. https://notreload.xyz/alumis-stock-crashes-in-classic-sell-the-news-after-strong-phase-3-psoriasis-data/
0 · Reply
Poester
Poester Mar. 30 at 4:02 PM
$ALMS Absurd. No reason why this is selling so hard.
0 · Reply
Omnitrader69
Omnitrader69 Mar. 30 at 3:59 PM
$ALMS why is this thing getting destroyed? I thought the data over the weekend was supposed to be good.
0 · Reply
erevnon
erevnon Mar. 30 at 3:07 PM
Oppenheimer maintains Alumis $ALMS at Outperform and raises the price target from $50 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
IN0V8
IN0V8 Mar. 30 at 2:49 PM
$ALMS H.C. Wainwright cuts target price to $25 from $40 Oppenheimer raises target price to $55 from $50
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 30 at 12:03 PM
$ALMS (+2.6% pre) Phase 3 win positions Alumis (NASDAQ: ALMS) psoriasis pill for 2026 NDA https://ooc.bz/l/97558
0 · Reply
Bullbear1010101
Bullbear1010101 Mar. 29 at 3:48 PM
$ALMS was $4.5 in august
0 · Reply
DonCorleone77
DonCorleone77 Mar. 29 at 3:39 PM
$ALMS Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib Alumis announced new data from its Phase 3 Onward1 and Onward2 clinical trials evaluating envudeucitinib, a next-generation, highly selective oral tyrosine kinase 2 inhibitor for moderate-to-severe plaque psoriasis. The data were presented in a late-breaking oral session at the 2026 AAD Annual Meeting. Envudeucitinib demonstrated robust skin clearance, achieving high thresholds of clinical response at Week 16 that continued to deepen through Week 24 in both trials. Psoriasis Area and Severity Index, PASI, 90 responses, which emerged as early as Week 4, were achieved by 59.9% and 53.1% of envudeucitinib patients at Week 16, increasing to 68.0% and 62.1% at Week 24. PASI 100 responses followed a similar trajectory, with 29.4% and 27.7% of envudeucitinib patients achieving complete skin clearance at Week 16, rising to 41.0% and 39.5% at Week 24.
0 · Reply
Latest News on ALMS
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Mar 28, 2026, 1:30 PM EDT - 7 days ago

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets

Mar 25, 2026, 12:39 PM EDT - 10 days ago

Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Mar 19, 2026, 4:05 PM EDT - 16 days ago

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Mar 18, 2026, 8:00 AM EDT - 17 days ago

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:05 AM EST - 4 weeks ago

Alumis to Present at the Leerink Partners Global Healthcare Conference

Alumis to Participate in Upcoming February Investor Conferences

Feb 5, 2026, 8:05 AM EST - 2 months ago

Alumis to Participate in Upcoming February Investor Conferences

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 9, 2026, 4:05 PM EST - 3 months ago

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Jan 7, 2026, 10:52 PM EST - 3 months ago

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Jan 7, 2026, 11:22 AM EST - 3 months ago

Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Alumis Announces Proposed Public Offering of Common Stock

Jan 6, 2026, 4:12 PM EST - 3 months ago

Alumis Announces Proposed Public Offering of Common Stock

Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars

Jan 6, 2026, 10:47 AM EST - 3 months ago

Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars

Alumis skin disease drug meets main goal of two late-stage trials

Jan 6, 2026, 7:07 AM EST - 3 months ago

Alumis skin disease drug meets main goal of two late-stage trials

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Jan 6, 2026, 7:00 AM EST - 3 months ago

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Jan 5, 2026, 5:00 PM EST - 3 months ago

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 13, 2025, 4:15 PM EST - 5 months ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 5 months ago

Alumis to Participate in Upcoming November Investor Conferences

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Sep 17, 2025, 4:53 AM EDT - 7 months ago

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Alumis to Participate in Upcoming September Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 7 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 8 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 9 months ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 9 months ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 11 months ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 11 months ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 11 months ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 11 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 11 months ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 1 year ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 1 year ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

Apr 14, 2025, 10:02 AM EDT - 1 year ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 1 year ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 1 year ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 1 year ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 1 year ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 1 year ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 1 year ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 1 year ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 1 year ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 1 year ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 1 year ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 1 year ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Oct 17, 2024, 2:32 PM EDT - 1 year ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 1 year ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 16, 2024, 4:32 PM EDT - 1 year ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 3 at 2:28 AM
$ALMS RSI: 45.78, MACD: -0.9569 Vol: 1.91, MA20: 24.85, MA50: 26.27 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
laaarsas
laaarsas Mar. 31 at 2:23 PM
$ALMS I see a lot of variation in the price targets for this one. They are not first movers. What’s their niche? How will they brake into the market? Why should one buy Alumis over something else?
1 · Reply
notreload_ai
notreload_ai Mar. 30 at 4:57 PM
$ALMS , $PTGX ... Alumis shares plunged after strong Phase 3 psoriasis data for envudeucitinib. HC Wainwright cuts price target to $25 citing rising competition. https://notreload.xyz/alumis-stock-crashes-in-classic-sell-the-news-after-strong-phase-3-psoriasis-data/
0 · Reply
Poester
Poester Mar. 30 at 4:02 PM
$ALMS Absurd. No reason why this is selling so hard.
0 · Reply
Omnitrader69
Omnitrader69 Mar. 30 at 3:59 PM
$ALMS why is this thing getting destroyed? I thought the data over the weekend was supposed to be good.
0 · Reply
erevnon
erevnon Mar. 30 at 3:07 PM
Oppenheimer maintains Alumis $ALMS at Outperform and raises the price target from $50 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
IN0V8
IN0V8 Mar. 30 at 2:49 PM
$ALMS H.C. Wainwright cuts target price to $25 from $40 Oppenheimer raises target price to $55 from $50
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 30 at 12:03 PM
$ALMS (+2.6% pre) Phase 3 win positions Alumis (NASDAQ: ALMS) psoriasis pill for 2026 NDA https://ooc.bz/l/97558
0 · Reply
Bullbear1010101
Bullbear1010101 Mar. 29 at 3:48 PM
$ALMS was $4.5 in august
0 · Reply
DonCorleone77
DonCorleone77 Mar. 29 at 3:39 PM
$ALMS Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib Alumis announced new data from its Phase 3 Onward1 and Onward2 clinical trials evaluating envudeucitinib, a next-generation, highly selective oral tyrosine kinase 2 inhibitor for moderate-to-severe plaque psoriasis. The data were presented in a late-breaking oral session at the 2026 AAD Annual Meeting. Envudeucitinib demonstrated robust skin clearance, achieving high thresholds of clinical response at Week 16 that continued to deepen through Week 24 in both trials. Psoriasis Area and Severity Index, PASI, 90 responses, which emerged as early as Week 4, were achieved by 59.9% and 53.1% of envudeucitinib patients at Week 16, increasing to 68.0% and 62.1% at Week 24. PASI 100 responses followed a similar trajectory, with 29.4% and 27.7% of envudeucitinib patients achieving complete skin clearance at Week 16, rising to 41.0% and 39.5% at Week 24.
0 · Reply
AlertsAndNews
AlertsAndNews Mar. 28 at 7:19 PM
$ALMS looks like theres a Dermatology Annual Meeting tons of headlines coming out about it. Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis "Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, and clear or almost clear scalp psoriasis emerged by Week 4, highlighting envudeucitinib's early onset and broad clinical benefit Conference call and webcast scheduled for March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT"
0 · Reply
jledet
jledet Mar. 27 at 5:12 PM
$ALMS https://seekingalpha.com/article/4885807-alumis-oral-psoriasis-med-can-win-approval-challenge-big-pharma-in-major-markets
0 · Reply
jledet
jledet Mar. 27 at 4:01 PM
$ALMS ready for the trend to reverse back upward! Hopefully back to $30 and beyond in the next couple weeks.
0 · Reply
Jonita
Jonita Mar. 26 at 2:43 PM
$ALMS in in in
0 · Reply
mlete21
mlete21 Mar. 26 at 1:55 PM
$ALMS
0 · Reply
G101SPM
G101SPM Mar. 25 at 7:10 PM
#SHOWTOME American Academy of Dermatology Meeting (March 26-28) Scheduled to appear: $ALMS, $ARQT, $KYMR, $MLTX, Ciena Corporation Annual General Meeting (March 26) Scheduled to appear: $CIEN
1 · Reply
laaarsas
laaarsas Mar. 22 at 2:47 PM
$ALMS What are people expecting here? Is ALMS really best in class now? What is their edge compared to competitors? They are not first movers which is a negative. How will they break into the market? What do they provide that is new?
0 · Reply
IN0V8
IN0V8 Mar. 20 at 3:36 PM
$ALMS Morgan Stanley raises target price to $38 from $33
0 · Reply
erevnon
erevnon Mar. 20 at 2:43 PM
Morgan Stanley maintains Alumis $ALMS at Overweight and raises the price target from $33 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Mar. 20 at 12:22 PM
Chardan Capital maintains Alumis $ALMS at Buy and raises the price target from $37 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Quantumup
Quantumup Mar. 18 at 2:40 PM
Truist reiterated $PTGX Buy; $110, $JNJ $ABVX $ALMS ABBV $TAK Truist said:::This morning, Protagonist (PTGX, Buy) and Johnson & Johnson (JNJ, NR) reported FDA approval of Icotyde (icotrokinra) in 12+ year old moderate to severe plaque psoriasis (PsO), marking Protagonist's official transition to a commercial company. We see strong differentiation as the first oral therapy with biologic-like efficacy in a TAM with ~8M patients, as per JNJ. We model $730M peak revenue to PTGX in royalties vs $560M consensus and note partner JNJ (JNJ, NR) estimates ico to present a~$5-10B market opportunity. With priority review for rusfertide (launch expected 2H26), we think this sets PTGX up to continue to deliver pipeline progress with strong cash position. Reiterate Buy.
1 · Reply
mlete21
mlete21 Mar. 16 at 2:39 PM
$ALMS consolidating!
0 · Reply